Recent Quotes (30 days)

You have no recent quotes
chg | %

bioasis Technologies Inc.  

(Public, CVE:BTI)   Watch this stock  
Find more results for BTI
1.05
0.00 (0.00%)
Delayed:   2:00PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.03 - 1.05
52 week 0.67 - 1.45
Open 1.03
Vol / Avg. 4,300.00/93,691.00
Mkt cap 43.90M
P/E     -
Div/yield     -
EPS -0.09
Shares 41.81M
Beta 0.78
Inst. own     -

Key stats and ratios

Q4 (Nov '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -96.16% -165.83%
Return on average equity -106.56% -177.77%
CDP Score - -

Address

Suite 600 1385 West 8th Avenue
VANCOUVER, BC V6H 3V9
Canada
+1-778-3833280 (Phone)
+1-604-2150091 (Fax)

Website links

Description

biOasis Technologies Inc. is an early stage biopharmaceutical company focused on research, development and commercialization of technologies and products intended for diagnosis and treatment of central nervous system (CNS) diseases and other disorders located within the brain. As of February 29, 2012, the Company was engaged in the development of a vector (Transcend) for the transport of therapeutic agents across the blood brain barrier (BBB), and the development of an in vitro diagnostic assay to assist physicians in diagnosis of Alzheimer´┐Żs disease (Cognitest). During the fiscal year ended February 29, 2012 (fiscal 2012), SISCAPA Assay Technologies, Inc., refined and streamlined the SISCAPA assay for p97. SISCAPA assays are being used as an analytical reference for the samples being evaluated in the Cognitest program.

Officers and directors

Robin B. Hutchison Chairman of the Board, President, Chief Executive Officer
Age: 56
David Clark Chief Financial Officer, Corporate Secretary, Director
Age: 55
Ronald P. Erickson Independent Director
Age: 67
H. Christian Fibiger PhD Independent Director
Greg D. Gubitz Independent Director
Age: 54
J. Michael Hutchison QC Independent Director
Age: 69
Terry Pearson Ph.D. Independent Director
Age: 66